The FDA's Orphan Drug Designation is a significant regulatory milestone that often leads to increased investor confidence and higher stock prices. This designation can provide benefits such as market exclusivity, tax credits, and reduced regulatory fees, which are likely to positively impact Candel Therapeutics' stock in the short term.